Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV.

In this study of 12 people with HIV who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4 counts, and vaccine reactions were generally mild.